ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Alpha Particle Targeted Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-1S17890
Home | Market Reports | Health| Nursing
Global Alpha Particle Targeted Therapy Market Research Report 2024
BUY CHAPTERS

Global Alpha Particle Targeted Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-1S17890
Report
October 2025
Pages:136
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Fusion Pharma
Bayer
Roche
Novartis
Orano Med
Oncoinvent AS
Perspective Therapeutics
Ablaze Pharma
ARTBIO
Astrazeneca plc
Advancell

Alpha Particle Targeted Therapy Market

The global Alpha Particle Targeted Therapy market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Basic Radiochemistry accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Alpha Particle Targeted Therapy leading manufacturers including Fusion Pharma, Bayer, Roche, Novartis, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, AstraZeneca, etc., dominate supply; the top five capture approximately % of global revenue, with Fusion Pharma leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Alpha Particle Targeted Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Alpha Particle Targeted Therapy Market Report

Report Metric Details
Report Name Alpha Particle Targeted Therapy Market
Segment by Type
  • Antibodies
  • Peptides or Small Molecules
Segment by Application
  • Basic Radiochemistry
  • Clinical Research
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Fusion Pharma, Bayer, Roche, Novartis, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, AstraZeneca, AdvanCell
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Alpha Particle Targeted Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Alpha Particle Targeted Therapy Market report?

Ans: The main players in the Alpha Particle Targeted Therapy Market are Fusion Pharma, Bayer, Roche, Novartis, Orano Med, Oncoinvent AS, Perspective Therapeutics, Ablaze Pharma, ARTBIO, AstraZeneca, AdvanCell

What are the Application segmentation covered in the Alpha Particle Targeted Therapy Market report?

Ans: The Applications covered in the Alpha Particle Targeted Therapy Market report are Basic Radiochemistry, Clinical Research

What are the Type segmentation covered in the Alpha Particle Targeted Therapy Market report?

Ans: The Types covered in the Alpha Particle Targeted Therapy Market report are Antibodies, Peptides or Small Molecules

1 Study Coverage
1.1 Introduction to Alpha Particle Targeted Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alpha Particle Targeted Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Antibodies
1.2.3 Peptides or Small Molecules
1.3 Market Segmentation by Application
1.3.1 Global Alpha Particle Targeted Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Basic Radiochemistry
1.3.3 Clinical Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Alpha Particle Targeted Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Alpha Particle Targeted Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Alpha Particle Targeted Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Alpha Particle Targeted Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Antibodies Market Size by Players
3.3.2 Peptides or Small Molecules Market Size by Players
3.4 Global Alpha Particle Targeted Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Alpha Particle Targeted Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Alpha Particle Targeted Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Alpha Particle Targeted Therapy Market Size by Type (2020-2031)
6.4 North America Alpha Particle Targeted Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Alpha Particle Targeted Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Alpha Particle Targeted Therapy Market Size by Type (2020-2031)
7.4 Europe Alpha Particle Targeted Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Alpha Particle Targeted Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Alpha Particle Targeted Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Alpha Particle Targeted Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Alpha Particle Targeted Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Alpha Particle Targeted Therapy Market Size by Type (2020-2031)
9.4 Central and South America Alpha Particle Targeted Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Alpha Particle Targeted Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Alpha Particle Targeted Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Alpha Particle Targeted Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Alpha Particle Targeted Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Fusion Pharma
11.1.1 Fusion Pharma Corporation Information
11.1.2 Fusion Pharma Business Overview
11.1.3 Fusion Pharma Alpha Particle Targeted Therapy Product Features and Attributes
11.1.4 Fusion Pharma Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.1.5 Fusion Pharma Alpha Particle Targeted Therapy Revenue by Product in 2024
11.1.6 Fusion Pharma Alpha Particle Targeted Therapy Revenue by Application in 2024
11.1.7 Fusion Pharma Alpha Particle Targeted Therapy Revenue by Geographic Area in 2024
11.1.8 Fusion Pharma Alpha Particle Targeted Therapy SWOT Analysis
11.1.9 Fusion Pharma Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Business Overview
11.2.3 Bayer Alpha Particle Targeted Therapy Product Features and Attributes
11.2.4 Bayer Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Bayer Alpha Particle Targeted Therapy Revenue by Product in 2024
11.2.6 Bayer Alpha Particle Targeted Therapy Revenue by Application in 2024
11.2.7 Bayer Alpha Particle Targeted Therapy Revenue by Geographic Area in 2024
11.2.8 Bayer Alpha Particle Targeted Therapy SWOT Analysis
11.2.9 Bayer Recent Developments
11.3 Roche
11.3.1 Roche Corporation Information
11.3.2 Roche Business Overview
11.3.3 Roche Alpha Particle Targeted Therapy Product Features and Attributes
11.3.4 Roche Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Roche Alpha Particle Targeted Therapy Revenue by Product in 2024
11.3.6 Roche Alpha Particle Targeted Therapy Revenue by Application in 2024
11.3.7 Roche Alpha Particle Targeted Therapy Revenue by Geographic Area in 2024
11.3.8 Roche Alpha Particle Targeted Therapy SWOT Analysis
11.3.9 Roche Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Alpha Particle Targeted Therapy Product Features and Attributes
11.4.4 Novartis Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Novartis Alpha Particle Targeted Therapy Revenue by Product in 2024
11.4.6 Novartis Alpha Particle Targeted Therapy Revenue by Application in 2024
11.4.7 Novartis Alpha Particle Targeted Therapy Revenue by Geographic Area in 2024
11.4.8 Novartis Alpha Particle Targeted Therapy SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Orano Med
11.5.1 Orano Med Corporation Information
11.5.2 Orano Med Business Overview
11.5.3 Orano Med Alpha Particle Targeted Therapy Product Features and Attributes
11.5.4 Orano Med Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Orano Med Alpha Particle Targeted Therapy Revenue by Product in 2024
11.5.6 Orano Med Alpha Particle Targeted Therapy Revenue by Application in 2024
11.5.7 Orano Med Alpha Particle Targeted Therapy Revenue by Geographic Area in 2024
11.5.8 Orano Med Alpha Particle Targeted Therapy SWOT Analysis
11.5.9 Orano Med Recent Developments
11.6 Oncoinvent AS
11.6.1 Oncoinvent AS Corporation Information
11.6.2 Oncoinvent AS Business Overview
11.6.3 Oncoinvent AS Alpha Particle Targeted Therapy Product Features and Attributes
11.6.4 Oncoinvent AS Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Oncoinvent AS Recent Developments
11.7 Perspective Therapeutics
11.7.1 Perspective Therapeutics Corporation Information
11.7.2 Perspective Therapeutics Business Overview
11.7.3 Perspective Therapeutics Alpha Particle Targeted Therapy Product Features and Attributes
11.7.4 Perspective Therapeutics Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Perspective Therapeutics Recent Developments
11.8 Ablaze Pharma
11.8.1 Ablaze Pharma Corporation Information
11.8.2 Ablaze Pharma Business Overview
11.8.3 Ablaze Pharma Alpha Particle Targeted Therapy Product Features and Attributes
11.8.4 Ablaze Pharma Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Ablaze Pharma Recent Developments
11.9 ARTBIO
11.9.1 ARTBIO Corporation Information
11.9.2 ARTBIO Business Overview
11.9.3 ARTBIO Alpha Particle Targeted Therapy Product Features and Attributes
11.9.4 ARTBIO Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.9.5 ARTBIO Recent Developments
11.10 AstraZeneca
11.10.1 AstraZeneca Corporation Information
11.10.2 AstraZeneca Business Overview
11.10.3 AstraZeneca Alpha Particle Targeted Therapy Product Features and Attributes
11.10.4 AstraZeneca Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 AdvanCell
11.11.1 AdvanCell Corporation Information
11.11.2 AdvanCell Business Overview
11.11.3 AdvanCell Alpha Particle Targeted Therapy Product Features and Attributes
11.11.4 AdvanCell Alpha Particle Targeted Therapy Revenue and Gross Margin (2020-2025)
11.11.5 AdvanCell Recent Developments
12 Alpha Particle Targeted TherapyIndustry Chain Analysis
12.1 Alpha Particle Targeted Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Alpha Particle Targeted Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Alpha Particle Targeted Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Fusion Pharma
Bayer
Roche
Novartis
Orano Med
Oncoinvent AS
Perspective Therapeutics
Ablaze Pharma
ARTBIO
Astrazeneca plc
Advancell
List of Tables
 Table 1. Global Alpha Particle Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Alpha Particle Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Alpha Particle Targeted Therapy Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Alpha Particle Targeted Therapy Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Alpha Particle Targeted Therapy Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Alpha Particle Targeted Therapy Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Alpha Particle Targeted Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alpha Particle Targeted Therapy as of 2024)
 Table 11. Global Alpha Particle Targeted Therapy Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Alpha Particle Targeted Therapy Companies Headquarters
 Table 13. Global Alpha Particle Targeted Therapy Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Alpha Particle Targeted Therapy Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Alpha Particle Targeted Therapy Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Alpha Particle Targeted Therapy Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Alpha Particle Targeted Therapy Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Alpha Particle Targeted Therapy High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Alpha Particle Targeted Therapy Growth Accelerators and Market Barriers
 Table 25. North America Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Alpha Particle Targeted Therapy Growth Accelerators and Market Barriers
 Table 27. Europe Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Alpha Particle Targeted Therapy Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Alpha Particle Targeted Therapy Investment Opportunities and Key Challenges
 Table 31. Central and South America Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Alpha Particle Targeted Therapy Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Alpha Particle Targeted Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Fusion Pharma Corporation Information
 Table 35. Fusion Pharma Description and Major Businesses
 Table 36. Fusion Pharma Product Features and Attributes
 Table 37. Fusion Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Fusion Pharma Revenue Proportion by Product in 2024
 Table 39. Fusion Pharma Revenue Proportion by Application in 2024
 Table 40. Fusion Pharma Revenue Proportion by Geographic Area in 2024
 Table 41. Fusion Pharma Alpha Particle Targeted Therapy SWOT Analysis
 Table 42. Fusion Pharma Recent Developments
 Table 43. Bayer Corporation Information
 Table 44. Bayer Description and Major Businesses
 Table 45. Bayer Product Features and Attributes
 Table 46. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Bayer Revenue Proportion by Product in 2024
 Table 48. Bayer Revenue Proportion by Application in 2024
 Table 49. Bayer Revenue Proportion by Geographic Area in 2024
 Table 50. Bayer Alpha Particle Targeted Therapy SWOT Analysis
 Table 51. Bayer Recent Developments
 Table 52. Roche Corporation Information
 Table 53. Roche Description and Major Businesses
 Table 54. Roche Product Features and Attributes
 Table 55. Roche Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Roche Revenue Proportion by Product in 2024
 Table 57. Roche Revenue Proportion by Application in 2024
 Table 58. Roche Revenue Proportion by Geographic Area in 2024
 Table 59. Roche Alpha Particle Targeted Therapy SWOT Analysis
 Table 60. Roche Recent Developments
 Table 61. Novartis Corporation Information
 Table 62. Novartis Description and Major Businesses
 Table 63. Novartis Product Features and Attributes
 Table 64. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. Novartis Revenue Proportion by Product in 2024
 Table 66. Novartis Revenue Proportion by Application in 2024
 Table 67. Novartis Revenue Proportion by Geographic Area in 2024
 Table 68. Novartis Alpha Particle Targeted Therapy SWOT Analysis
 Table 69. Novartis Recent Developments
 Table 70. Orano Med Corporation Information
 Table 71. Orano Med Description and Major Businesses
 Table 72. Orano Med Product Features and Attributes
 Table 73. Orano Med Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Orano Med Revenue Proportion by Product in 2024
 Table 75. Orano Med Revenue Proportion by Application in 2024
 Table 76. Orano Med Revenue Proportion by Geographic Area in 2024
 Table 77. Orano Med Alpha Particle Targeted Therapy SWOT Analysis
 Table 78. Orano Med Recent Developments
 Table 79. Oncoinvent AS Corporation Information
 Table 80. Oncoinvent AS Description and Major Businesses
 Table 81. Oncoinvent AS Product Features and Attributes
 Table 82. Oncoinvent AS Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. Oncoinvent AS Recent Developments
 Table 84. Perspective Therapeutics Corporation Information
 Table 85. Perspective Therapeutics Description and Major Businesses
 Table 86. Perspective Therapeutics Product Features and Attributes
 Table 87. Perspective Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Perspective Therapeutics Recent Developments
 Table 89. Ablaze Pharma Corporation Information
 Table 90. Ablaze Pharma Description and Major Businesses
 Table 91. Ablaze Pharma Product Features and Attributes
 Table 92. Ablaze Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Ablaze Pharma Recent Developments
 Table 94. ARTBIO Corporation Information
 Table 95. ARTBIO Description and Major Businesses
 Table 96. ARTBIO Product Features and Attributes
 Table 97. ARTBIO Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. ARTBIO Recent Developments
 Table 99. AstraZeneca Corporation Information
 Table 100. AstraZeneca Description and Major Businesses
 Table 101. AstraZeneca Product Features and Attributes
 Table 102. AstraZeneca Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. AstraZeneca Recent Developments
 Table 104. AdvanCell Corporation Information
 Table 105. AdvanCell Description and Major Businesses
 Table 106. AdvanCell Product Features and Attributes
 Table 107. AdvanCell Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 108. AdvanCell Recent Developments
 Table 109. Raw Materials Key Suppliers
 Table 110. Distributors List
 Table 111. Market Trends and Market Evolution
 Table 112. Market Drivers and Opportunities
 Table 113. Market Challenges, Risks, and Restraints
 Table 114. Research Programs/Design for This Report
 Table 115. Key Data Information from Secondary Sources
 Table 116. Key Data Information from Primary Sources


List of Figures
 Figure 1. Alpha Particle Targeted Therapy Product Picture
 Figure 2. Global Alpha Particle Targeted Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Antibodies Product Picture
 Figure 4. Peptides or Small Molecules Product Picture
 Figure 5. Global Alpha Particle Targeted Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Basic Radiochemistry
 Figure 7. Clinical Research
 Figure 8. Alpha Particle Targeted Therapy Report Years Considered
 Figure 9. Global Alpha Particle Targeted Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Alpha Particle Targeted Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Alpha Particle Targeted Therapy Revenue Market Share by Region (2020-2031)
 Figure 13. Global Alpha Particle Targeted Therapy Revenue Market Share Ranking (2024)
 Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 15. Antibodies Revenue Market Share by Player in 2024
 Figure 16. Peptides or Small Molecules Revenue Market Share by Player in 2024
 Figure 17. Global Alpha Particle Targeted Therapy Revenue Market Share by Type (2020-2031)
 Figure 18. Global Alpha Particle Targeted Therapy Revenue Market Share by Application (2020-2031)
 Figure 19. North America Alpha Particle Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 20. North America Top 5 Players Alpha Particle Targeted Therapy Revenue (US$ Million) in 2024
 Figure 21. North America Alpha Particle Targeted Therapy Revenue (US$ Million) by Type (2020 - 2031)
 Figure 22. North America Alpha Particle Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 23. US Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 24. Canada Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 25. Mexico Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 26. Europe Alpha Particle Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. Europe Top 5 Players Alpha Particle Targeted Therapy Revenue (US$ Million) in 2024
 Figure 28. Europe Alpha Particle Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 29. Europe Alpha Particle Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 30. Germany Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 31. France Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 32. U.K. Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 33. Italy Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 34. Russia Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Alpha Particle Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Top 8 Players Alpha Particle Targeted Therapy Revenue (US$ Million) in 2024
 Figure 37. Asia-Pacific Alpha Particle Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 38. Asia-Pacific Alpha Particle Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 39. Indonesia Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 40. Japan Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 41. South Korea Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 42. Australia Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 43. India Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 44. Indonesia Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 45. Vietnam Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 46. Malaysia Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 47. Philippines Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 48. Singapore Alpha Particle Targeted Therapy Revenue (2020-2031) & (US$ Million)
 Figure 49. Central and South America Alpha Particle Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Central and South America Top 5 Players Alpha Particle Targeted Therapy Revenue (US$ Million) in 2024
 Figure 51. Central and South America Alpha Particle Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 52. Central and South America Alpha Particle Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 53. Brazil Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 54. Argentina Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 55. Middle East and Africa Alpha Particle Targeted Therapy Revenue YoY (2020-2031) & (US$ Million)
 Figure 56. Middle East and Africa Top 5 Players Alpha Particle Targeted Therapy Revenue (US$ Million) in 2024
 Figure 57. South America Alpha Particle Targeted Therapy Revenue (US$ Million) by Type (2020-2031)
 Figure 58. Middle East and Africa Alpha Particle Targeted Therapy Revenue (US$ Million) by Application (2020-2031)
 Figure 59. GCC Countries Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 60. Israel Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 61. Egypt Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 62. South Africa Alpha Particle Targeted Therapy Revenue (2020-2025) & (US$ Million)
 Figure 63. Alpha Particle Targeted Therapy Industry Chain Mapping
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Single-Use Bioprocessing Film Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15C20068
Thu Oct 16 00:00:00 UTC 2025

Add to Cart

Global Site Management Organization (SMO) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19O20066
Wed Oct 15 00:00:00 UTC 2025

Add to Cart

Global Virtual ICU Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-13D20078
Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Alpha Particle Targeted Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-1S17890
Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions